SLRX קפיטליזציה חשבונאית salariuspharma.com

Salarius Pharmaceuticals (SLRX) developments in targeted oncology therapy are independent of economic cycles or seasonality, demonstrating high macro-resilience. The company maintains authority in epigenetics, creating tools for the reprogramming of malignant cells. This chart shows current share prices are fixed at 0.03. The business relies on the speed of validating new molecules to preempt the market entry of affordable generics from pharma behemoths.

Salarius Pharmaceuticals (SLRX) is currently optimizing its oncology portfolio amid R&D restructuring and a reduction in clinical trial expenditures. By analyzing the equity volume chart on the balance sheet, an investor assesses the difference between all assets and liabilities, which allows for the determination of the real value of net assets and an evaluation of the delisting risk in the event of a critical decline in the issuer's financial stability.